Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

Core Insights - Sarepta Therapeutics reported a fourth-quarter 2025 adjusted loss of $3.58 per share, significantly wider than the Zacks Consensus Estimate of a loss of 71 cents, primarily due to increased operating expenses [1][3] - The company experienced a nearly 33% year-over-year decline in total revenues, totaling $442.9 million, although this figure exceeded the Zacks Consensus Estimate of $408.5 million [3][9] - Sarepta's stock fell 5% in after-market trading following the earnings report, and the stock has declined 12% year-to-date compared to the industry's 9% growth [3] Financial Performance - The adjusted figures for the quarter exclude various costs, resulting in a reported loss of $3.93 per share compared to an EPS of $1.50 in the same period last year [2] - Product revenues fell 42% year over year to $369.6 million, with sales from three PMO therapies totaling $259 million, a 2% increase year over year, but below the Zacks Consensus Estimate of $270 million [4] - Elevidys sales generated $110 million, down over 71% year over year, missing the Zacks Consensus Estimate of $114 million due to a suspension of shipments to non-ambulatory patients [5] Revenue Breakdown - Collaboration and other revenues increased to approximately $73.3 million from $20.3 million in the previous year, driven by higher contract manufacturing revenues [6] - For the full year 2025, Sarepta reported total revenues of $2.2 billion, reflecting a 16% year-over-year increase, while the adjusted loss per share was $5.05 compared to an adjusted EPS of $3.71 in the prior year [8] Guidance and Future Outlook - Management provided guidance for 2026, projecting net product revenues between $1.2 billion and $1.4 billion, with total collaboration and contract manufacturing revenues expected to be between $450 million and $550 million [10] - The company anticipates combined adjusted R&D and SG&A expenses in the range of $800 million to $900 million [10] Pipeline Developments - CEO Douglas Ingram announced plans to retire by the end of 2026, prompting a search for a new CEO [11] - Sarepta is addressing safety concerns related to Elevidys by developing a revised treatment protocol and has initiated dosing in a new cohort of the phase Ib ENDEAVOR study [14] - The company has shifted focus to siRNA programs acquired from Arrowhead Pharmaceuticals, which include several investigational therapies [15][16]